Asset Impairment, Restructuring, and Other Special Charges

6 Months Ended

Jun. 30, 2022

Restructuring and Related Activities [Abstract]

Asset Impairment, Restructuring, and Other Special Charges

The components of the charges included in asset impairment, restructuring, and other special charges in our consolidated condensed statements of operations are described below.


	Six Months Ended June 30,
		2022		2021
Severance		$	—	$	11.5
Asset impairment and other special charges		—		200.1
Total asset impairment, restructuring, and other special charges		$	—	$	211.6

There were no asset impairment, restructuring, and other special charges recognized during the three months ended June 30, 2022 and 2021.

Asset impairment, restructuring, and other special charges recognized during the six months ended June 30, 2021 were primarily related to an intangible asset impairment of $108.1 million resulting from the sale of the rights to Qbrexza®, as well as acquisition and integration costs associated with the acquisition of Prevail.

We recognized inventory impairment charges related to our COVID-19 antibodies of $423.0 million and $504.5 million during the three and six months ended June 30, 2021, respectively, in cost of sales in our consolidated condensed statements of operations. As part of our response to the COVID-19 pandemic, and at the request of the U.S. and international governments, we invested in large-scale manufacturing of COVID-19 antibodies at risk, in order to ensure rapid access to patients around the world. As the COVID-19 pandemic evolved during 2021, we incurred inventory impairment charges primarily due to the combination of changes to demand from U.S. and international governments, including changes to our agreement with the U.S. government, and near-term expiry dates of COVID-19 antibodies.